secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001193125-25-180889
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Q2 net loss $9.9M; Phase 2b IKT-001 PAH trial to start H2 2025
-------------------------------------------------------------------------

- Cash and marketable securities $87.7M at June 30, 2025, vs $97.5M at Dec 31, 2024.
- Net loss $9.9M ($0.11/share) for Q2 2025 vs $5.0M ($0.66/share) in Q2 2024.
- R&D expenses $5.3M in Q2 2025, up from $3.1M in Q2 2024; SG&A $5.9M vs $2.0M.
- Phase 2b IMPROVE-PAH study of IKT-001 (prodrug of imatinib) to begin H2 2025.
- Primary endpoint: change in pulmonary vascular resistance at Week 26; secondary include 6MWD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525180889/0001193125-25-180889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525180889/d946023d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-180889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer